<DOC>
	<DOC>NCT00731263</DOC>
	<brief_summary>The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.</brief_summary>
	<brief_title>A Study of Tor Kinase Inhibitor in Advanced Tumors</brief_title>
	<detailed_description />
	<criteria>Histological or cytological confirmation of an advanced solid malignant tumour (or lymphoma Part A only) Cancer which is refractory to standard therapies or for which no standard therapy exists, patients with measurable or nonmeasurable disease (according to RECIST criteria) can be recruited to Part A Evidence of postmenopausal status or negative urine/serum pregnancy test for premenopausal female patients Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug. Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advance solid tumours</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Preliminary efficacy</keyword>
	<keyword>AZD8055</keyword>
	<keyword>Tor kinase inhibitor</keyword>
	<keyword>Oral administration</keyword>
</DOC>